Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Cheraghchi-Bashi A"'
Autor:
Thomas G. Hayhow, Beth Williamson, Mandy Lawson, Natalie Cureton, Erin L. Braybrooke, Andrew Campbell, Rodrigo J. Carbajo, Azadeh Cheraghchi-Bashi, Elisabetta Chiarparin, Coura R. Diène, Charlene Fallan, David I. Fisher, Frederick W. Goldberg, Lorna Hopcroft, Philip Hopcroft, Anne Jackson, Jason G. Kettle, Teresa Klinowska, Ulrike Künzel, Gillian Lamont, Hilary J. Lewis, Gareth Maglennon, Scott Martin, Pablo Morentin Gutierrez, Christopher J. Morrow, Myria Nikolaou, J. Willem M. Nissink, Patrick O’Shea, Radoslaw Polanski, Markus Schade, James S. Scott, Aaron Smith, Judith Weber, Joanne Wilson, Bin Yang, Claire Crafter
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-17 (2024)
Abstract Targeting the estrogen receptor alpha (ERα) pathway is validated in the clinic as an effective means to treat ER+ breast cancers. Here we present the development of a VHL-targeting and orally bioavailable proteolysis-targeting chimera (PROT
Externí odkaz:
https://doaj.org/article/ec006f9560824ea494be6041bb1eeb60
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Rebecca Carter, Azadeh Cheraghchi-Bashi, Adam Westhorpe, Sheng Yu, Yasmin Shanneik, Elena Seraia, Djamila Ouaret, Yasuhiro Inoue, Catherine Koch, Jenny Wilding, Daniel Ebner, Anderson J. Ryan, Francesca M. Buffa, Ricky A. Sharma
Publikováno v:
Cancer Biology & Medicine, Vol 16, Iss 2, Pp 234-246 (2019)
Objective Patients with BRAF-mutant colorectal cancer (CRC) have a poor prognosis. Molecular status is not currently used to select which drug to use in combination with radiotherapy. Our aim was to identify drugs that radiosensitise CRC cells with k
Externí odkaz:
https://doaj.org/article/20f6deba4d8f477f8d7767514aae6c9b
Autor:
Sabina C. Cosulich, Jason S. Carroll, Robert McEwen, Igor Chernukhin, Mandy Lawson, Azadeh Cheraghchi-Bashi, Urszula M. Polanska, Anna D. Staniszewska, Larissa S. Carnevalli, Jon O. Curwen, Oona Delpuech, Rasmus Siersbaek, Claire Crafter, Chrysiis Michaloglou
Supplementary Figure S1. Vistusertib (AZD2014) causes a decrease in RB phosphorylation in the absence of cell cycle arrest. Supplementary Figure S2. Different mTOR inhibitors in combination with palbociclib cause a decrease in cell viability. Supplem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d2971446864fbedb32439af08aab612
https://doi.org/10.1158/1535-7163.22510243
https://doi.org/10.1158/1535-7163.22510243
Autor:
Sabina C. Cosulich, Jason S. Carroll, Robert McEwen, Igor Chernukhin, Mandy Lawson, Azadeh Cheraghchi-Bashi, Urszula M. Polanska, Anna D. Staniszewska, Larissa S. Carnevalli, Jon O. Curwen, Oona Delpuech, Rasmus Siersbaek, Claire Crafter, Chrysiis Michaloglou
The cyclin dependent kinase (CDK)–retinoblastoma (RB)–E2F pathway plays a critical role in the control of cell cycle in estrogen receptor–positive (ER+) breast cancer. Small-molecule inhibitors of CDK4/6 have shown promise in this tumor type in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a430fac5fb19944258d4dc125065e6b
https://doi.org/10.1158/1535-7163.c.6539551.v1
https://doi.org/10.1158/1535-7163.c.6539551.v1
Autor:
Morteza Shams, Saeed Heydaryan, Mehdi Cheraghchi Bashi, Bahman Noroozi Gorgani, Ezatollah Ghasemi, Hamidreza Majidiani, Naser Nazari, Hamid Irannejad
Publikováno v:
In Silico Pharmacology. 11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e991384cd882a33370d9edc4e48b3df5
https://doi.org/10.1007/s40203-023-00140-w
https://doi.org/10.1007/s40203-023-00140-w
Autor:
Theresa Proia, Yann Wallez, Azadeh Cheraghchi Bashi, Zena Wilson, Suzanne Randle, Mark Anderton, Danielle Carroll, Zeshaan Rasheed, J. Elizabeth Pease, Elisabetta Leo, Jerome Mettetal
Publikováno v:
Cancer Research. 82:P2-13
Background: Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate composed of an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor approved for HER2+ metastatic breast and gastric cancer. Clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1cdfe22321666477da9208b409f3b3ca
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-18
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-18
Autor:
Azadeh Cheraghchi Bashi, Theresa Proia, Suzanne Randle, Mark Anderton, Zeshaan Rasheed, J. Elizabeth Pease, Simon Barry, Danielle Carroll, Jerome Mettetal
Publikováno v:
Cancer Research. 82:P2-13
Background: Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate composed of an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor approved for HER2+ metastatic breast and gastric cancer. Clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e5809b5e8d67e3e81b3847ffaa20a15
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-23
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-23
Autor:
Carter, Rebecca1,2, Cheraghchi-Bashi, Azadeh2, Westhorpe, Adam1,2, Sheng Yu3, Shanneik, Yasmin2, Seraia, Elena4, Ouaret, Djamila5, Yasuhiro Inoue6, Koch, Catherine7, Wilding, Jenny5, Ebner, Daniel8, Ryan, Anderson J.9, Buffa, Francesca M.9, Sharma, Ricky A.1,2 ricky.sharma@ucl.ac.uk
Publikováno v:
Cancer Biology & Medicine. May2019, Vol. 16 Issue 2, p235-246. 19p.